Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

HGS To Focus On “Core Pipeline” As Part Of Cost-Cutting; CEO Steps Down

Executive Summary

Human Genome Sciences is implementing a cost reduction program to focus its resources on clinical development of its immunology/infectious disease and oncology drug candidates

You may also be interested in...



R&D Should Be Outsourced Overseas To Control Development Costs – HGS CEO

Drug companies should consider outsourcing R&D work to other countries in light of cost pressures in the U.S., Human Genome Sciences CEO William Haseltine, PhD, said

R&D Should Be Outsourced Overseas To Control Development Costs – HGS CEO

Drug companies should consider outsourcing R&D work to other countries in light of cost pressures in the U.S., Human Genome Sciences CEO William Haseltine, PhD, said

Second Continuous Marketing Application Pilot Program Is 44% Enrolled

Enrollment in FDA's second continuous marketing application pilot program is nearly 50% enrolled

Latest Headlines
See All
UsernamePublicRestriction

Register

PS043622

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel